Journal of Gastrointestinal Cancer

, Volume 43, Issue 2, pp 157–167

Pancreatic Involvement by Plasma Cell Neoplasms




Pancreatic involvement by plasma cell neoplasms is an extremely rare event, with only 50 cases described in the literature. They can present as a primary solitary extramedullary plasmacytoma or plasmacytoma secondary to a plasma cell myeloma. Clinical manifestations are due to the presence of a pancreatic mass usually in the pancreas head, which causes extra-biliary obstruction and abdominal pain.


Abdominal imaging including CT scan or endoscopic ultrasound with fine-needle aspiration tissue sampling is essential for the initial diagnostic procedure. However, immunohistochemical analysis of the biopsy specimen or flow cytometry of the aspirated material is crucial to prove the monoclonality and the final diagnosis of a plasma cell neoplasm.


Management of these situations include radiotherapy, chemotherapy, surgery or combined therapy. Novel medications including the immunomodulatory drugs or the proteasome inhibitors followed by consolidation with intensive chemotherapy and haematopoietic stem cell transplantation are nowadays used as upfront treatment in the cases associated to a plasma cell myeloma.


Despite the rarity, plasma cell neoplasms should be considered in the differential diagnosis of obstructive jaundice and pancreatic neoplasms since they are potentially treatable situations.


Pancreas Plasma cell neoplasms Extramedullary plasmacytomas Plasma cell myeloma Obstructive jaundice 


  1. 1.
    Saif MW. Primary pancreatic lymphomas. JOP. 2006;7:262–73.PubMedGoogle Scholar
  2. 2.
    Swerdlow SH, Campo E, Harry NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues; 2008.Google Scholar
  3. 3.
    Tomita T. Amyloidosis of pancreatic islets in primary amyloidosis (AL type). Pathol Int. 2005;55:223–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Höppener JW, Nieuwenhuis MG, Vroom TM, Lips CJ. Islet amyloid and diabetes mellitus type 2. Ned Tijdschr Geneeskd. 2000;144:1995–2000.PubMedGoogle Scholar
  5. 5.
    Gandhi GY, Basu R, Dispenzieri A, Basu A, Montori VM, Brennan MD. Endocrinopathy in POEMS syndrome: the Mayo Clinic experience. Mayo Clin Proc. 2007;82:836–42.PubMedCrossRefGoogle Scholar
  6. 6.
    Alexiou C, Kau RJ, Dietzfelbinger H, et al. Extramedullary plasmacytoma: tumour occurence and therapeutic concepts. Cancer. 1999;85:2305–14.PubMedCrossRefGoogle Scholar
  7. 7.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66.PubMedCrossRefGoogle Scholar
  8. 8.
    Ries LA, et al., editors. SEER Cancer Statistics Review, 1975–2001. National Cancer Institute, Bethesda, MD; 2004.Google Scholar
  9. 9.
    Anon. Criteria for the classification of monoclonal gammophaties, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–57.CrossRefGoogle Scholar
  10. 10.
    Hefferman A. Plasmacytoma of pancreas and duodenum causing acute intestinal obstruction. Lancet. 1947;1:910.PubMedCrossRefGoogle Scholar
  11. 11.
    Richards WG, Katzmann FS, Coleman FC. Extramedullary plasmacytoma arising in the head of the pancreas: report of a case. Cancer. 1958;11:649–52.PubMedCrossRefGoogle Scholar
  12. 12.
    Doutre LP, Leger H, Bobois JP, Diard F. Extra skeletal plasmacytic sarcoma located in the pancreas. Chirurgie. 1976;102:130–5.PubMedGoogle Scholar
  13. 13.
    Simon TL, Rughani IK, Pierson DJ, Hebard DW. Multiple plasmacytomas with thoracic and biliary involvement. Arch Intern Med. 1978;138:1165–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Rice NT, Woodring JH, Mostowycz L, Purcell M. Pancreatic plasmacytoma: sonographic and computerized tomographic findings. J Clin Ultrasound. 1981;9:46–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Bell HG, David R, Shamsuddin AM. Extrahepatic biliary obstruction and liver failure secondary to myeloma of the pancreas. Hum Pathol. 1982;13:940–2.PubMedCrossRefGoogle Scholar
  16. 16.
    Twomey BP, Katz D. Computed tomography in the diagnosis of extramedullary plasmacytoma. J Comput Tomogr. 1983;7:407–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Borgia G, Ciampi R, Nappa S, Vallone G, Iovinella V, Crowell J. Clinical and diagnostic considerations on a case of pancreatic plasmacytoma. Minerva Med. 1984;75:2839–42.PubMedGoogle Scholar
  18. 18.
    Borgia G, Ciampi R, Nappa S, Iovinella V, Crowell J. Pancreatic plasmacytoma: an unusual cause of obstructive jaundice. Arch Pathol Lab Med. 1984;108:773–4.PubMedGoogle Scholar
  19. 19.
    Helenon O, Bonnel D, Bigot JM, Carette MF, Pene F. Plasmacytoma of the head of the pancreas. Diagnosis by puncture aspiration guided by echography. Presse Med. 1984;13:2645.PubMedGoogle Scholar
  20. 20.
    Görg C, Schwerk W, Görg K, Pflüger KH, Havemann K. Extrahepatic biliary obstruction caused by infiltration of the pancreas by plasmacytoma. Klin Wochenschr. 1985;63:718–21.PubMedCrossRefGoogle Scholar
  21. 21.
    Jaubert D, Hauteville D, Verdier M, et al. Plasmacytoma of the head of the pancreas: a rare cause of cholestatic jaundice. Gastroenterol Clin Biol. 1985;9:532–4.PubMedGoogle Scholar
  22. 22.
    Mitchell DG, Hill MC. Obstructive jaundice due to multiple myeloma of the pancreatic head: CT evaluation. J Comput Assist Tomogr. 1985;9:1118–9.PubMedGoogle Scholar
  23. 23.
    Speelberg B, Kluin PM, Punt K, Lips CJ. Non-secreting extramedullary plasmacytoma with late involvement of the pancreas causing obstructive jaundice. Neth J Med. 1985;28:291–94.PubMedGoogle Scholar
  24. 24.
    Zafaranloo S, Bryk D, Gerard PS. Obstructive jaundice secondary to multiple myeloma—a case report. Comput Radiol. 1986;10:197–200.PubMedCrossRefGoogle Scholar
  25. 25.
    Scheiman J, Elta G, Francis I. Biliary obstruction secondary to an extramedullary plasmacytoma of the pancreas: confusion with pancreatitis on computed tomography. Pancreas. 1987;2:237–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Akiyama H, Krigel RL. Metastatic extramedullary plasmacytoma: a case report and review of the literature of a rare pseudocarcinoma. Am J Hematol. 1988;27:115–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Fukuya T, Yoshimitsu K, Kitagawa S, Murakami J, Masuda K, Nakamura K. Plasmacytoma of the pancreatic head. Gastrointest Radiol. 1989;14:226–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Wilson TE, Korobkin M, Francis IR. Pancreatic plasmacytoma: CT findings. AJR Am J Roentgenol. 1989;152:1227–8.PubMedGoogle Scholar
  29. 29.
    Brichon P, Solary E, Caillot D, Boussuge C, et al. Extramedullary pancreatic localization of myeloma. Ann Med Interne (Paris). 1989;140:421–2.Google Scholar
  30. 30.
    Hamamoto K, Kosaka C, Takeno M, et al. Multiple myeloma causing obstructive jaundice by extramedullary plasmacytoma after Bence Jones protein loss—an autopsy case report. Rinsho Ketsueki. 1990;31:57–61.PubMedGoogle Scholar
  31. 31.
    Fischer A, Suhrland MJ, Vogl SE. Myeloma of the head of the pancreas. A case report Cancer. 1991;67:681–3.Google Scholar
  32. 32.
    Davidson BS, Lee JE, Dodd LG, Dimopoulos MA, Evans DB. Extramedullary plasmacytoma of the pancreas. Am J Clin Oncol. 1993;16:363–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Olson MC, Kalbhen CL, Posniak HV. Pancreatic plasmacytomas in a patient with multiple myeloma: CT and ultrasound findings. Abdom Imaging. 1993;18:323–4.PubMedCrossRefGoogle Scholar
  34. 34.
    Fautrel B, Marolleau JP, Charleux F, Brice P, Frija J, Gisselbrecht C. Pancreatic and hepatic plasmocytomas: an exceptional case. Nouv Rev Fr Hematol. 1993;35:125–8.PubMedGoogle Scholar
  35. 35.
    Tanaka Y, Samma S, Hayashi Y, et al. A case of retroperitoneal extramedullary plasmacytoma. Hinyokika Kiyo. 1993;39:639–43.PubMedGoogle Scholar
  36. 36.
    Ohno T, Saka Y, Horii J, et al. Aggressive transformation of an indolent myeloma with abdominal extramedullary plasmacytoma after 6-year period of observation. Rinsho Ketsueki. 1994;35:390–6.PubMedGoogle Scholar
  37. 37.
    Dodd LG, Evans DB, Symmans F, Katz RL. Fine-needle aspiration of pancreatic extramedullary plasmacytoma: possible confusion with islet cell tumor. Diagn Cytopathol. 1994;10:371–4.PubMedCrossRefGoogle Scholar
  38. 38.
    Abu-Hammour AM, Venu RP, Etzkorn KP, Showel JL, Zaytsev PM, Brown RD. Common bile duct obstruction caused by multiple myeloma of the pancreas. Gastrointest Endosc. 1996;44:606–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Pääkkö E, Autio R, Lähde S. Plasmacytoma of the pancreas: CT and MRI appearance. Rofo. 1998;169:673–5.PubMedCrossRefGoogle Scholar
  40. 40.
    Ríos A, Ramírez P, Majado MA, Parrilla P. Obstructive jaundice caused by pancreatic head tumor secondary to IgG multiple myeloma. Rev Esp Enferm Dig. 2000;92:475–6.PubMedGoogle Scholar
  41. 41.
    Hirata S, Yamaguchi K, Bandai S, Izumo A, Chijiiwa K, Tanaka M. Secondary extramedullary plasmacytoma involving the pancreas. J Hepatobiliary Pancreat Surg. 2002;9:111–5.PubMedCrossRefGoogle Scholar
  42. 42.
    Balliu E, Casas JD, Barluenga E, Guasch I. Multifocal involvement of the pancreas in multiple myeloma: sonographic, CT, and MR imaging findings. AJR Am J Roentgenol. 2003;180:545–6.PubMedGoogle Scholar
  43. 43.
    Hiller N, Goitein O, Ashkenazi YJ. Plasmacytoma of the pancreas. Isr Med Assoc J. 2004;6:704–5.PubMedGoogle Scholar
  44. 44.
    Coban S, Koklu S, Ertugrul I, Kuzu I, Bahar K. Obstructive jaundice in a patient with multiple myeloma. J Gastroenterol Hepatol. 2004;19:837–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Deguchi Y, Nonaka A, Takeuchi E, Funaki N, Kono Y, Mizuta K. Primary pancreatic plasmacytoma. Am J Clin Oncol. 2004;27:247–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Kazama T, Ng CS, Giralt SA. Multiphasic CT and MRI appearances of extramedullary multiple myeloma involving the stomach, pancreas, and bladder. Clin Imaging. 2005;29:263–5.PubMedCrossRefGoogle Scholar
  47. 47.
    Ali R, Ozkalemkas F, Ozcelik T, et al. Extramedullary plasmacytoma involving the abdominal vessels and pancreas. Dig Dis Sci. 2007;52:3199–201.PubMedCrossRefGoogle Scholar
  48. 48.
    Hameed A, Ryan M, Kamel D, Vusirikala M. Plasmacytoma of the pancreas and pelvis: a case report. Lab Hematol. 2008;14:10–1.Google Scholar
  49. 49.
    Atiq M, Ali SA, Dang S, et al. Pancreatic plasmacytoma presenting as variceal hemorrhage: life threatening complication of a rare entity. JOP. 2009;10:187–8.PubMedGoogle Scholar
  50. 50.
    Spiegel A, Patel R, Pais S. Obstructive jaundice secondary to a pancreatic plasmacytoma. Clin Gastroenterol Hepatol. 2009;7:A32.PubMedCrossRefGoogle Scholar
  51. 51.
    Gupta P, Rice GD, Abraham K, Ghole V, Ketkar M. Extramedullary plasmacytoma of the pancreas and jejunum. Clin Imaging. 2009;33:240–3.PubMedCrossRefGoogle Scholar
  52. 52.
    Leake PA, Coard KC, Plummer JM. Extramedullary plasmacytoma of the pancreas as an uncommon cause of obstructive jaundice: a case report. J Med Case Reports. 2009;3:8785.PubMedCrossRefGoogle Scholar
  53. 53.
    Wei JY, Tong HY, Zhu WF, et al. Bortezomib in treatment of extramedullary plasmacytoma of the pancreas. Hepatobiliary Pancreat Dis Int. 2009;8:329–31.PubMedGoogle Scholar
  54. 54.
    Annibali O, Marchesi F, Petrucci MT, Tirindelli MC, Avvisati G. Relapse of IgA lambda multiple myeloma presenting as obstructive jaundice and abdominal pain. Onkologie. 2009;32:119–21.PubMedCrossRefGoogle Scholar
  55. 55.
    Padda MS, Milless T, Adeniran AJ, Mahooti S, Aslanian HR. Pancreatic and gastric plasmacytoma presenting with obstructive jaundice, diagnosed with endoscopic ultrasound-guided fine needle aspiration. Case Rep Gastroenterol. 2010;4:410–5.PubMedCrossRefGoogle Scholar
  56. 56.
    Coss A, Zhou C, Byrne MF, Weiss AA. Relapse of multiple myeloma presenting with biliary obstruction. Can J Gastroenterol. 2010;24:237–8.PubMedGoogle Scholar
  57. 57.
    Artifon E, Okawa L, Baba E, Moura E, Sakai P, Savides T. Diagnosis of pancreatic plasmacytoma by endoscopic ultrasound-fine needle aspiration. Rev Gastroenterol Mex. 2010;75:357–9.Google Scholar
  58. 58.
    Pinto-Marques P, Martins C, Mendonça E, Castro H, Serra D. Pancreatic head mass of unusual etiology: multiple myeloma diagnosed by endoscopic ultrasound-guided fine needle aspiration. Endoscopy. 2010;42 Suppl 2:E263–4.PubMedCrossRefGoogle Scholar
  59. 59.
    Gritzmann N, Macheiner P, Hollerweger A, Hübner E. CT in the differentiation of pancreatic neoplasms—progress report. Dig Dis. 2004;22:6–17.PubMedCrossRefGoogle Scholar
  60. 60.
    Kauhanen SP, Komar G, Seppänen MP, et al. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg. 2009;250:957–63.PubMedCrossRefGoogle Scholar
  61. 61.
    Farma JM, Santillan AA, Melis M, et al. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol. 2008;15:2465–71.PubMedCrossRefGoogle Scholar
  62. 62.
    Itani KM, Taylor TV, Green LK. Needle biopsy for suspicious lesions of the head of the pancreas: pitfalls and implications for therapy. J Gastrointest Surg. 1997;1:337–41.PubMedCrossRefGoogle Scholar
  63. 63.
    Turner BG, Cizginer S, Agarwal D, Yang J, Pitman MB, Brugge WR. Diagnosis of pancreatic neoplasia with EUS and FNA: a report of accuracy. Gastrointest Endosc. 2010;71:91–8.PubMedCrossRefGoogle Scholar
  64. 64.
    Sheridan MB, Ward J, Guthrie JA, et al. Dynamic contrast-enhanced MR imaging and dual-phase helical CT in the preoperative assessment of suspected pancreatic cancer: a comparative study with receiver operating characteristic analysis. AJR Am J Roentgenol. 1999;173:583–90.PubMedGoogle Scholar
  65. 65.
    Adamek HE, Albert J, Breer H, Weitz M, Schilling D, Riemann JF. Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study. Lancet. 2000;356:190–3.PubMedCrossRefGoogle Scholar
  66. 66.
    Yamaguchi K, Chijiwa K, Shimizu S, Yokohata K, Morisaki T, Tanaka M. Comparison of endoscopic retrograde and magnetic resonance cholangiopancreatography in the surgical diagnosis of pancreatic diseases. Am J Surg. 1998;175:203–8.PubMedCrossRefGoogle Scholar
  67. 67.
    Islam S, Callery MP. Primary pancreatic lymphoma—a diagnosis to remember. Surgery. 2001;129:380–3.PubMedCrossRefGoogle Scholar
  68. 68.
    Salvatore JR, Cooper B, Shah I, Kummet T. Primary pancreatic lymphoma: a case report, literature review, and proposal for nomenclature. Med Oncol. 2000;17:237–47.PubMedCrossRefGoogle Scholar
  69. 69.
    van Gulik TM, Moojen TM, van Geenen R, Rauws EA, Obertop H, Gouma DJ. Differential diagnosis of focal pancreatitis and pancreatic cancer. Ann Oncol. 1999;10 Suppl 4:85–8.PubMedCrossRefGoogle Scholar
  70. 70.
    Mayr NA, Wen BC, Hussey DH, et al. The role of radiation therapy in the treatment of solitary plasmacytomas. Radiother Oncol. 1990;17:293–303.PubMedCrossRefGoogle Scholar
  71. 71.
    Jyothirmayi R, Gangadharan VP, Nair MK, Rajan B. Radiotherapy in the treatment of solitary plasmacytoma. Br J Radiol. 1997;70:511–6.PubMedGoogle Scholar
  72. 72.
    Kumar S, Rajkumar SV. Thalidomide and dexamethasone: therapy for multiple myeloma. Expert Rev Anticancer Ther. 2005;5:759–66.PubMedCrossRefGoogle Scholar
  73. 73.
    Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;20:4319.PubMedCrossRefGoogle Scholar
  74. 74.
    Wang M, Weber D, Delasalle K, et al. Thalidomide–dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol. 2005;79:194.PubMedCrossRefGoogle Scholar
  75. 75.
    Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine–doxorubicin–dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005;106:35.PubMedCrossRefGoogle Scholar
  76. 76.
    Paubelle E, Coppo P, Garderet L, et al. Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractorymultiple myeloma who failed all other therapies includinghematopoietic stem cell transplantation: possibleenhancement of graft-vs-tumor effect. Leukemia. 2005;19:1702–4.PubMedCrossRefGoogle Scholar
  77. 77.
    Krauth MT, Bankier A, Valent P, Kalhs P, Drach J. Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavilypretreated, relapsed multiple myeloma after treatment with bortezomib. Leuk Res. 2005;29:1473–7.PubMedCrossRefGoogle Scholar
  78. 78.
    Laura R, Cibeira MT, Uriburu C, et al. Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur JHaematol. 2006;76:405–8.CrossRefGoogle Scholar
  79. 79.
    Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91.PubMedCrossRefGoogle Scholar
  80. 80.
    Fermand JP, Katsahian S, Divine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005;23:9227.PubMedCrossRefGoogle Scholar
  81. 81.
    Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875.PubMedCrossRefGoogle Scholar
  82. 82.
    Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood. 2004;104:3052.PubMedCrossRefGoogle Scholar
  83. 83.
    Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370:1209.PubMedCrossRefGoogle Scholar
  84. 84.
    Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol. 2009;27:3664.PubMedCrossRefGoogle Scholar
  85. 85.
    Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367:825.PubMedCrossRefGoogle Scholar
  86. 86.
    Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood. 2006;108:2165.PubMedCrossRefGoogle Scholar
  87. 87.
    Durue BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer. 1975;36:842–54.CrossRefGoogle Scholar
  88. 88.
    Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Hospital Santo António dos Capuchos–CHLCLisbonPortugal

Personalised recommendations